Adverse drug events (ADEs) may cause serious injuries including death. Spontaneous reporting of ADEs plays a great role in detection and prevention of them, however, underreporting always exists. Although several interventions have been utilized to solve this problem, they are mainly based on experience and the rationale for choosing them has no theoretical base. The vast variety of behavioral ...

Who could disagree with the seemingly common-sense reasoning that: “We must learn from the things that go wrong.”? Despite major investments to improve patient safety, relatively few evaluations demonstrate convincing reductions in risk, harm, serious error or death. This disappointing trajectory of improvement from learning from errors or Safety-I as it is sometimes known has led some research...

Objective.\p=m-\To identify and evaluate the systems failures that underlie errors causing adverse drug events (ADEs) and potential ADEs. Design.\p=m-\Systemsanalysis of events from a prospective cohort study. Participants.\p=m-\Alladmissions to 11 medical and surgical units in two tertiary care hospitals over a 6-month period. Main Outcome Measures.\p=m-\Errors,proximal causes, and systems fai...

Adverse drug events are common in older patients, particularly in those taking at least five medications, but such events are predictable and often preventable. A rational approach to prescribing in older adults integrates physiologic changes of aging with knowledge of pharmacology. Focusing on specific outcomes, such as the prompt recognition of adverse drug events, allows the family physician...

A standardized, controlled vocabulary allows adverse drug events (ADE) information to be described in an unambiguous way in knowledge bases, which is critical for clinical decision support systems for patient medication safety. In this paper, we describe our preliminary effort on development of an ontological representation pattern for the ADE domain. We discuss clinical implications of the eff...

Identification of reliable markers to predict drug-related adverse events (DRAEs) is an important goal of the pharmaceutical industry and others within the healthcare community. We have used genetic polymorphisms, including the most frequent source of variation (single nucleotide polymorphisms, SNPs) in the human genome, in pharmacogenetic approaches designed to predict DRAEs. Three studies exe...